Madrid, Community of Madrid, Spain
A C-level biotechnology executive, Board Chair, Board Member and venture builder with extensive international experience (Spain, UK, Ireland, Italy, Denmark, Norway, Sweden, Estonia, Türkiye, Tunisia, and Uruguay). My focus is guiding life science ventures from academic spin-out to successful exit. I have a track record of 30 years in: - Company Formation & Fundraising: Building ventures from concept, securing VC funding, and preparing companies for successful IPOs and M&A. - IP & Licensing Strategy: Creating foundational patent portfolios and negotiating high-value licensing deals. - Business Development & M&A: Leading global BD, managing due diligence, and executing company sale processes. - Mentoring & Lecturing: Acting as an expert mentor for leading European programmes (EIC Scaling Club, EIT Health, NOME) and lecturing on technology protection and commercialisation (NTNU in Norway, IE Business School in Madrid, University of Cambridge)
Ventac Partners is a dedicated life science investment and consulting firm with offices in Europe, USA, Latin America, Asia and Australasia. Ventac Partners has a strong track record in founding new innovative companies, strategic and operational market and product analysis, intellectual property development, fund raising, licensing, M&A and strategy consulting. All partners are experienced executives from pharma, biotech and medtech companies, and preclinical, clinical and regulatory, legal and intellectual property experts with extensive backgrounds in successfully starting, growing and expanding international life science companies.
ArrayPatch is a University College Cork (UCC) spin-out developing DerMap™, a patented, polymer-free dissolving microneedle drug delivery platform that allows up to 100% drug loading for small molecules and peptides. Backed by the first close of its €3M seed round from institutional and syndicate investors, the business is advancing its platform technology, across broad applications, into clinical development via an abbreviated pathway for reformulated approved medicines.
I manage business development and IP strategy for Cube Labs and its portfolio of 17 healthcare technology companies created from Italian academic innovation. This includes evaluating new opportunities, guiding licensing and partnerships, and supporting early-stage ventures. In March 2023, Cube Labs completed a EUR 4.1M IPO on Euronext Growth Milan.
Eolo Pharma is a clinical-stage biotechnology company pioneering new approaches to treat obesity and metabolic disease. By targeting the body’s energy expenditure pathways, we aim to develop transformative therapies that go beyond traditional weight-loss mechanisms. Our lead candidate, MVD-1, is the first compound shown to safely activate creatine-dependent thermogenesis in humans, a novel biological process with the potential to reset metabolic health. Backed by over a decade of research, our work reflects a commitment to advancing science-driven solutions that improve lives worldwide.
Inhibitec Anticuerpos SL was founded in 2019 (Santander, Spain) with the goal of introducing new treatments for patients with autoimmune/chronic inflammatory diseases like psoriasis, psoriatic arthritis, and rheumatoid arthritis, based on the blockade of BAMBI (BMP and Activin Membrane-Bound Inhibitor). Inhibitec is a spin off company from the University of Cantabria - with technology from a group led by Dr. Jesus Merino, MD, PhD - and from the Spanish National Research Council (CSIC) - with technology from a group led by Dr. Ramon Merino, MD, PhD.